1 Min Read
March 30 (Reuters) - Glenmark Pharmaceuticals Ltd:
* Reports positive results from a phase 3 trial of GSP 301, mometasone/olopatadine fixed-dose combination nasal spray
* Phase 3, U.S.-based trial was a four-arm, double-blind, randomized, parallel group, active and placebo-controlled study
* Study enrolled 1,176 adults and adolescents 12 years of age and older for 14-days of twice daily treatment with GSP 301, mometasone, olopatadine or placebo.
* Says all trial arms utilized same vehicle and nasal spray delivery system
* Primary endpoint was change from baseline in average morning and evening patient-reported 12-hour reflective total nasal symptom score (RTNSS) Source text for Eikon: Further company coverage: